2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension

TSOC pulmonary hypertension committee

研究成果: Article同行評審

5 引文 斯高帕斯(Scopus)

摘要

Pulmonary arterial hypertension (PAH) is characterized as a progressive and sustained increase in pulmonary vascular resistance, which may induce right ventricular failure. In 2014, the Working Group on Pulmonary Hypertension of the Taiwan Society of Cardiology (TSOC) conducted a review of data and developed a guideline for the management of PAH.4 In recent years, several advancements in diagnosis and treatment of PAH has occurred. Therefore, the Working Group on Pulmonary Hypertension of TSOC decided to come up with a focused update that addresses clinically important advances in PAH diagnosis and treatment. This 2018 focused update deals with: (1) the role of echocardiography in PAH; (2) new diagnostic algorithm for the evaluation of PAH; (3) comprehensive prognostic evaluation and risk assessment; (4) treatment goals and follow-up strategy; (5) updated PAH targeted therapy; (6) combination therapy and goal-orientated therapy; (7) updated treatment for PAH associated with congenital heart disease; (8) updated treatment for PAH associated with connective tissue disease; and (9) updated treatment for chronic thromboembolic pulmonary hypertension.

原文English
頁(從 - 到)1584-1609
頁數26
期刊Journal of the Formosan Medical Association
118
發行號12
DOIs
出版狀態Published - 2019 十二月

All Science Journal Classification (ASJC) codes

  • Medicine(all)

指紋 深入研究「2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension」主題。共同形成了獨特的指紋。

引用此